NEOsphere Biotechnologies

NEOsphere Biotechnologies is a pioneering proteomics company that creates value through strategic partnerships, aiming to systematically discover and develop therapeutic degradation targets not accessible by traditional small-molecule approaches. The company uses cutting-edge mass spectrometry technology to routinely screen tens of thousands of compounds against a proteome of over 10,000 proteins. A specially constructed data processing system extracts high-probability candidates, which are validated at an unprecedented depth of 50,000 sites through mechanistic approaches such as ubiquitin analysis, to become novel degrader targets. NEOsphere Biotechnologies’ integrated target discovery system connects innovative degrader chemistry with previously undruggable proteomes, revealing new entry points for drug development and generating a broad pipeline of first-in-class therapeutics.